Detalhe da pesquisa
1.
Loss of SLCO1B3 drives taxane resistance in prostate cancer.
Br J Cancer
; 115(6): 674-81, 2016 09 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-27537383
2.
Association of Survival Benefit With Docetaxel in Prostate Cancer and Total Number of Cycles Administered: A Post Hoc Analysis of the Mainsail Study.
JAMA Oncol
; 3(1): 68-75, 2017 Jan 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-27560549
3.
Inter-patient variability in docetaxel pharmacokinetics: A review.
Cancer Treat Rev
; 41(7): 605-13, 2015 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-25980322
4.
Targeting the Androgen Receptor Confers In Vivo Cross-resistance Between Enzalutamide and Docetaxel, But Not Cabazitaxel, in Castration-resistant Prostate Cancer.
Eur Urol
; 67(6): 981-985, 2015 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-25484141
5.
Initial biopsy Gleason score as a predictive marker for survival benefit in patients with castration-resistant prostate cancer treated with docetaxel: data from the TAX327 study.
Eur Urol
; 66(2): 330-6, 2014 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-23957945
6.
Nuclear Eg5 (kinesin spindle protein) expression predicts docetaxel response and prostate cancer aggressiveness.
Oncotarget
; 5(17): 7357-67, 2014 Sep 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-25277178
7.
Reply to Masaki Shiota and Akira Yokomizo's Letter to the Editor re: Robert J. van Soest, Ellen S. de Morrée, Charlotte F. Kweldam, et al. Targeting the Androgen Receptor Confers In Vivo Cross-resistance Between Enzalutamide and Docetaxel, But Not Cabazitaxel, in Castration-resistant Prostate Cancer. Eur Urol 2015;67:981-5.
Eur Urol
; 69(3): e43-4, 2016 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-26233533